June 9, 2022. Our Chairman Shi Yuanyuan and Chief Scientist Wang Jianxun led the company team to Shenzhen Hospital of Hong Kong University for learning and exchange with Director Wang Jun of Hematology Department. Director Wang Jun introduced in detail the clinical treatment effect and treatment plan of CAR-T medicine, as well as the physical and mental conditions of patients in the treatment process; Chairman Shi Yuanyuan and Professor Wang Jianxun introduced the advantages of retrovirus in CAR-T R&D and production and the technical details of CAR-T drugs from R&D to clinical stage. The two sides discussed the development of cell therapy industry and the difficulties of clinical treatment, hoping to promote the application and development of cell therapy in tumor treatment from initial research and development, clinical trials, industrial production, patient care and other aspects. Both sides reached a consensus on future oriented cooperation in clinical research of cell therapy.2022年6月9日。我司董事长史渊源，首席科学家王建勋带领公司团队前往香港大学深圳医院与血液科王钧主任进行学习交流。王均主任详细介绍了CAR-T药物在临床上的治疗效果、治疗方案以及病人在治疗过程中的身体和精神状况；史渊源董事长和王建勋教授介绍了逆转录病毒在CAR-T研发生产上的优势以及CAR-T药物从研发到临床阶段的技术细节。双方探讨了细胞治疗行业发展和临床治疗的难点，希望从初期研发、临床试验、工业化生产，病人护理关怀等各方面着手促进细胞疗法在肿瘤治疗上的运用与发展。双方达成面向未来的在细胞治疗临床研究方面的合作共识。